A Study of Durvalumab (MEDI4736) in Esophageal Cancer

Status Completed

Clinical Trial Summary

This is a phase II, open-label, single arm, single-stage study. A total of 23 evaluable patients will be enrolled. If total number of patients free of disease relapse at 1 year is less than or equal to 15, the drug would not be considered for further study in this setting. After six patients are treated with at least one dose of study drug, they will be observed for a minimum of 60 days. During the 60-day observation period, further accrual will be halted to evaluate "unacceptable toxicities warranting early closure of the trial" defined as: - Any definitive durvalumab-related death. A durvalumab-related death will be continuously monitored throughout the trial and the trial will be suspended for re-evaluation whenever such an event is confirmed. - Any unexpected and previously unreported grade 4 toxicities definitely related to durvalumab.

Clinical Trial Description

OUTLINE: This is a multi-center trial. INVESTIGATIONAL TREATMENT: Subjects will receive durvalumab 1500 mg IV every 4 weeks (1 cycle) for a maximum 13 doses (12 months), or until unacceptable toxicities or disease recurrence. The following baseline labs must be completed within 28 days prior to registration for protocol therapy: Hematopoietic: - White blood cell count (WBC) > 3 K/mm^3 - Hemoglobin (Hgb) > 9 g/dL. Transfusion is allowed, if needed, since patients are post esophagectomy. - Platelets > 100 K/mm^3 - Absolute neutrophil count (ANC) ≥ 1.5 K/mm^3 Renal: - Calculated creatinine clearance of >/= 40 cc/min using the Cockcroft-Gault formula or by 24-hour urine collection. Hepatic: - Bilirubin ≤ 1.5 x upper limit of normal (ULN) - Aspartate aminotransferase (AST, SGOT) </= 2.5 x ULN - Alanine aminotransferase (ALT, SGPT) </= 2.5 x ULN ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02639065
Study type	Interventional
Source	Big Ten Cancer Research Consortium
Contact
Status	Completed
Phase	Phase 2
Start date	April 27, 2016
Completion date	June 9, 2021

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT06006390` - CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors	Phase 1/Phase 2
Terminated	`NCT01624090` - Mithramycin for Lung, Esophagus, and Other Chest Cancers	Phase 2
Recruiting	`NCT05787522` - Efficacy and Safety of AI-assisted Radiotherapy Contouring Software for Thoracic Organs at Risk
Not yet recruiting	`NCT05542680` - Study on the Design and Application of Special Semi Recumbent Cushion for Postoperative Patients With Esophageal Cancer	N/A
Completed	`NCT03384511` - The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies.	Phase 4
Completed	`NCT00003864` - Docetaxel Plus Carboplatin in Treating Patients With Advanced Cancer of the Esophagus	Phase 2
Recruiting	`NCT05491616` - Nivolumab During Active Surveillance After Neoadjuvant Chemoradiation for Esophageal Cancer: SANO-3 Study	Phase 2
Active, not recruiting	`NCT04383210` - Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors	Phase 2
Completed	`NCT00199849` - NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine	Phase 1
Completed	`NCT03756597` - PAN-study: Pan-Cancer Early Detection Study (PAN)
Completed	`NCT00400114` - Sutent Following Chemotherapy, Radiation and Surgery For Resectable Esophageal Cancer	Phase 2
Completed	`NCT03652077` - A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies	Phase 1
Recruiting	`NCT04615806` - The Value of Lymph Node Dissection of Indocyanine Green-guided Near-infrared Fluorescent Imaging in Esophagectomy	N/A
Active, not recruiting	`NCT04566367` - Blue Laser Imaging (BLI) for Detection of Secondary Head and Neck Cancer	N/A
Active, not recruiting	`NCT03962179` - Feasibility and Efficacy of a Combination of a SEMS and Vacuum Wound Treatment (VACStent)	N/A
Terminated	`NCT01446874` - Prevention of Post-operative Pneumonia (POPP)	Phase 2/Phase 3
Completed	`NCT03468634` - Raman Probe for In-vivo Diagnostics (During Oesophageal) Endoscopy	N/A
Active, not recruiting	`NCT02869217` - Study of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patients With Solid Tumors	Phase 1
Completed	`NCT02810652` - Perioperative Geriatrics Intervention for Older Cancer Patients Undergoing Surgical Resection	N/A
Recruiting	`NCT02544737` - Apatinib for Metastatic Esophageal Cancer.	Phase 2